APGE250117C70000
- 0.35
- 0.000.00%
Apogee Therapeutics Newsroom
This Apogee Therapeutics Insider Increased Their Holding In The Last Year
Apogee Therapeutics Director Mark McKenna Acquires $990,775 in Stock
Guggenheim Reiterates Buy on Apogee Therapeuticsto Buy
Apogee Therapeutics Advances Clinical Trials for APG333
Express News | Apogee Therapeutics Inc - Interim Data From Phase 1 Trial Expected in 2H 2025
Express News | Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of Apg333, Its Novel Half-Life Extended Tslp Antibody for the Treatment of Respiratory and Broader I&I Conditions
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, Its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions
Promising Potential of Apogee Therapeutics: A Buy Rating Backed by Innovative Pipeline and Strategic Approach
TD Cowen Sticks to Its Buy Rating for Apogee Therapeutics, Inc. (APGE)
CCORF Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $89
Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics, Inc. (APGE) and TransMedics Group (TMDX)
Express News | Apogee Therapeutics Inc : Jefferies Raises Target Price to $82 From $75
Express News | Wedbush raised Apogee Therapeutics' target price from $87.00 to $90.00.
Wedbush Adjusts Price Target on Apogee Therapeutics to $90 From $87, Maintains Outperform Rating
Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day
Guggenheim Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Raises Target Price to $110
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
CCORF Initiates Apogee Therapeutics(APGE.US) With Buy Rating, Announces Target Price $89
Apogee Therapeutics Price Target Announced at $89.00/Share by Canaccord Genuity
Apogee Therapeutics Initiated at Buy by Canaccord Genuity